Source-grounded facts extracted from ImageneBio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ImageneBio, Inc. shareholders approved 2025 Amended Plan at the 2026-06-16 meeting.
“Proposal 3: 2025 Amended Plan The Company’s stockholders approved the Amended Plan. The final voting results are as follows: For Against Abstain Broker Non-Votes 6,322,909 591,191 106,688 612,769”
ImageneBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-16 meeting.
“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: For Against Abstain 7,613,075 20,477 5”
ImageneBio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.
“Proposal 1: Election of Directors The Company’s stockholders elected the following two individuals to serve as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified or until his earlier death, resignation or removal. The final voting results are as follows: For Withheld Broker Non-Votes David P. Bonita, M.D. 6,980,671 40,117 612,769 Joseph P. Slattery 6,985,414 35,374 612,769”
ImageneBio, Inc. reported financial results for quarter ended March 31, 2026.
“On May 7, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
ImageneBio, Inc. issued up to 5,770,335 Warrant Shares of warrant to certain institutional and accredited investors for purchase price of $5.199 per Warrant Share.
“pre-funded warrants to purchase up to 5,770,335 Warrant Shares at a purchase price of $5.199 per Warrant Share to the Investors for gross proceeds to the Company of approximately $30 million”
ImageneBio, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at gross proceeds to the Company of approximately $30 million (effective 2026-04-12).
“On April 12, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue pre-funded warrants to purchase shares of the Company’s voting common stock”
ImageneBio, Inc. reported financial results for the quarter and fiscal year ended December 31, 2025.
“On March 10, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2025.”
ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals (closed 2025-07-25).
“On July 25, 2025, the Delaware corporation formerly known as "Ikena Oncology, Inc." completed its previously announced merger with Inmagene Biopharmaceuticals, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands ("Inmagene"), in accordance with the terms of the Agreement and Plan of Merger, dated as of December 23, 2024”
ImageneBio, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On August 2, 2025, upon the approval of the Audit Committee, PricewaterhouseCoopers LLP ("PwC") was appointed as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025”
ImageneBio, Inc. dismissed Ernst & Young LLP as its auditor.
“dismissed Ernst & Young LLP ("EY") as the Company’s independent registered public accounting firm, with such dismissal to become effective on August 2, 2025”
ImageneBio, Inc.: Company ceased to be a shell company as a result of the Merger.
“As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.”
ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals for Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock (closed 2025-07-25).
“Time were canceled and ceased to exist, and no consideration was delivered in exchange therefor, (b) each then-outstanding Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock, par value $0.001 per share (“ Ikena Common Stock ”) (such ratio, the “ Exchange Ratio ”) and (c) each then-outstanding option to purchase Inmagene”
Jotin Marango was appointed as Chief Operating Officer at ImageneBio, Inc..
“On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.”
ImageneBio, Inc. announced a restructuring with charges of approximately $1.2 million in cash expenditures affecting company-wide (clinical programs IK-930 and IK-595) (approximately 53%).
“the Restructuring Plan during the three months ended June 30, 2024 related to employee severance and related termination benefits, which are expected to result in approximately $1.2 million in cash expenditures. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose”
Sergio Santillana resigned as Chief Medical Officer at ImageneBio, Inc..
“On February 20, 2024, Sergio Santillana, M.D., M.Sc., MBA, notified Ikena Oncology, Inc. (the “Company”) of his decision to resign from his role at the Company as Chief Medical Officer effective as of February 29, 2024, with his last day of employment being March 5, 2024 (the “Departure Date”).”
ImageneBio, Inc. announced a restructuring with charges of approximately $1.6 million affecting discovery organization, as well as select employees working in development and general and administrative functions (approximately 35%).
“to the discontinuation of its discovery efforts and expects to recognize these charges during the three months ended March 31, 2024, of which aggregate charges of approximately $1.6 million relate to the Workforce Reduction. Expenses related to the Workforce Reduction consist of employee severance and related termination benefits, and are expected to result in”
ImageneBio, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 9, 2023, Ikena Oncology, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.”
ImageneBio, Inc. shareholders approved Issuance of common stock upon conversion of Series A Non-Voting Convertible Preferred Stock in connection with the acquisition of Pionyr Immunotherapeutics, Inc. at the 2023-10-11 meeting.
“The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), the issuance of the Company’s common stock, par value $0.001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (“Proposal No. 1"), issued in connection with the acquisition of Pionyr Immunotherapeutics, Inc. (the “Acquisition”). The votes cast at the Special Meeting were as follows: For Against Abstain 25,681,604 12,086 1,156”
ImageneBio, Inc.: Filed Certificate of Designation establishing Series A Non-Voting Convertible Preferred Stock (effective 2023-08-04).
“On August 4, 2023, Ikena filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger referenced in Item 1.01 above.”
ImageneBio, Inc. completed an acquisition involving Pionyr Immunotherapeutics, Inc. (closed 2023-08-04).
“On August 4, 2023, Ikena completed its business combination with Pionyr.”
ImageneBio, Inc. entered into CVR Agreement with Ikena and the Rights Agent.
“In connection with the Merger, Ikena and the Rights Agent (as defined therein) entered into a contingent value rights agreement (the “ CVR Agreement ”)”
ImageneBio, Inc. entered into Lock-up Agreements with certain Pionyr securityholders.
“Concurrently and in connection with the execution of the Merger Agreement, certain Pionyr securityholders as of immediately prior to the Merger entered into lock-up agreements with Ikena and Pionyr”
ImageneBio, Inc. entered into Support Agreements with certain stockholders of Ikena.
“In connection with the execution of the Merger Agreement, Ikena and Pionyr entered into stockholder support agreements (the “ Support Agreements ”) with certain stockholders of Ikena.”
ImageneBio, Inc. entered into Merger Agreement with Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc..
“Under the terms of the Merger Agreement, outstanding options to acquire Pionyr Common Stock (each, a “ Company Option ”) that had an exercise price greater than the Per Share Cash Consideration (as defined in the Merger Agreement) were cancelled”
ImageneBio, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(d)).
“June 30, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in response to a self-reported discovery and resolution of non-compliance with Listing Rule 5635(d). The letter notified the Company of the Staff’s determination that the Company had failed to comply with Listing Rule 5635(d), as well as the Staff’s determination that the Company had remediated the deficiency and regained compliance with Listing Rule 5635(d), and the matter is now closed, as further desc”
ImageneBio, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.
“The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 26,385,702 9,069 1,307 0”
ImageneBio, Inc. shareholders approved Election of Class II Directors: David Bonita, M.D., Jean-François Formela, M.D., and Richard Wooster, Ph.D. at the 2023-06-09 meeting.
“The votes cast at the Annual Meeting were as follows: For Withheld Broker Non-Votes David Bonita, M.D. 16,468,374 7,623,868 2,303,836 Jean-François Formela, M.D. 20,781,723 3,310,519 2,303,836 Richard Wooster, Ph.D. 20,784,244 3,307,998 2,303,836”
ImageneBio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters valued at approximately $40,020,500 million (effective 2023-05-15).
“On May 15, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten registered offering (the “Offering”) of 6,110,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price of $6.550 per share, less underwriting discounts and commissions.”
Ronald Renaud resigned as Chairman of the Board at ImageneBio, Inc..
“On December 15, 2022, Ronald Renaud notified the Company of his intent to resign from the Company’s Board and from his positions as Chairman of the Board, Chair of the Audit Committee of the Board and member of the Compensation Committee of the Board, effective December 15, 2022.”
Owen Hughes was appointed as Chairman of the Board at ImageneBio, Inc..
“On December 15, 2022, Mr. Hughes filled the vacated positions on the committees of the Board and became the Chairman of the Board”
Jotin Marango was appointed as Chief Financial Officer, Head of Corporate Development at ImageneBio, Inc..
“appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022”
Douglas R. Carlson resigned as other_named_officer at ImageneBio, Inc..
“This appointment has been made in connection with the effectiveness of the resignation of Douglas R. Carlson, as previously disclosed on January 28, 2022”
Francisco Olivera was appointed as acting Principal Accounting Officer at ImageneBio, Inc..
“On February 18, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Francisco Olivera as the acting Principal Accounting Officer of the Company.”
Francisco Oliveira was appointed as Principal Accounting Officer at ImageneBio, Inc..
“Francisco Oliveira, the Head of Finance and Administration since 2019, will serve as Principal Accounting Officer and report directly to the Company’s Chief Executive Officer, Mark Manfredi, on an interim basis effective as of Mr. Carlson’s departure, while a formal search process to appoint a new Chief Financial Officer is conducted.”
Douglas R. Carlson resigned as Chief Operating Officer and Executive Vice President of Finance at ImageneBio, Inc..
“On January 28, 2022, Douglas R. Carlson informed Ikena Oncology, Inc. (the “Company”) of his intent to resign as Chief Operating Officer and Executive Vice President of Finance of the Company to pursue other professional opportunities with broader responsibility.”
Richard Wooster was appointed as Director at ImageneBio, Inc..
“On January 21, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Dr. Richard Wooster to fill a newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.